A randomized, double-blind, placebo-controlled trial of pregnenolone for bipolar depression

Neuropsychopharmacology

Volumn 39, Issue 12, 2014, Pages 2867-2873

  Brown, E Sherwood ^a   Park, John ^a   Marx, Christine E ^b,c   Hynan, Linda S ^a   Gardner, Claire ^a   Davila, Domingo ^a   Nakamura, Alyson ^a   Sunderajan, Prabha ^a   Lo, Alexander ^a   Holmes, Traci ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ELTANOLONE; PREGNENOLONE;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; BLOOD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREGNANOLONE; PREGNENOLONE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84936772127     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.138     Document Type: Article

References (51)

1. Akwa Y, Purdy RH, Koob GF, Britton KT (1999). The amygdala mediates the anxiolytic-like effect of the neurosteroid allopregnanolone in rat. Behav Brain Res 106:119-125.
2. Angst J (1998). The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 50:143-151.
3. Baulieu EE (1998). Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 23:963-987.
4. Bianchi M, Baulieu EE (2012). 3beta-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders. Proc Natl Acad Sci USA 109:1713-1718.
5. Bschor T, Angst J, Azorin JM, Bowden CL, Perugi G, Vieta E et al (2012). Are bipolar disorders underdiagnosed in patients with depressive episodes? Results of the multicenter BRIDGE screening study in Germany. J Affect Disord 142:45-52.
6. Carta MG, Bhat KM, Preti A (2012). GABAergic neuroactive steroids: a new frontier in bipolar disorders? Behav Brain Funct 8:61.
7. Cook JB, Werner DF, Maldonado-Devincci AM, Leonard MN, Fisher KR, O'Buckley TK et al (2014). Overexpression of the steroidogenic enzyme cytochrome P450 side chain cleavage in the ventral tegmental area increases 3alpha, 5alpha-THP and reduces long-term operant ethanol self-administration. J Neurosci 34:5824-5834.
8. Daray FM, Thommi SB, Ghaemi SN (2010). The pharmacogenetics of antidepressant-induced mania: a systematic review and metaanalysis. Bipolar Disord 12:702-706.
9. El-Mallakh RS, Ghaemi SN, Sagduyu K, Thase ME, Wisniewski SR, Nierenberg AA et al (2008). Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord 111:372-377.
10. Espallergues J, Mamiya T, Vallee M, Koseki T, Nabeshima T, Temsamani J et al (2012). The antidepressant-like effects of the 3beta-hydroxysteroid dehydrogenase inhibitor trilostane in mice is related to changes in neuroactive steroid and monoamine levels. Neuropharmacology 62:492-502.
11. Ferrari AJ, Baxter AJ, Whiteford HA (2011). A systematic review of the global distribution and availability of prevalence data for bipolar disorder. J Affect Disord 134:1-13.
12. First M, Spitzer R, Gibbon M, Williams J B W (1995). Structured Clinical Interview for DSM-IV Axis I Disorders. Biometrics Research Department, New York State Psychiatric Institute, Department of Psychiatry, Columbia University: New York, NY, USA.
13. Flood JF, Morley JE, Roberts E (1992). Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it. Proc Natl Acad Sci USA 89:1567-1571.
14. Fontaine-Lenoir V, Chambraud B, Fellous A, David S, Duchossoy Y, Baulieu E-E et al (2006). Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. Proc Natl Acad Sci USA 103:4711-4716.
15. George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM (1994). CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI. Biol Psychiatry 35:775-780.
16. Ghaemi SN, Boiman EE, Goodwin FK (2000). Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 61:804-808.
17. Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME et al (2010). Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 71:372-380.
18. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang SH (2003). The health and productivity cost burden of the "top 10" physical and mental health conditions affecting six large US employers in 1999. J Occup Environ Med 45:5-14.
19. Gomez C, Saldivar-Gonzalez A, Delgado G, Rodriguez R (2002). Rapid anxiolytic activity of progesterone and pregnanolone in male rats. Pharmacol Biochem Behav 72:543-550.
20. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
21. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
22. Hoertel N, Le Strat Y, Angst J, Dubertret C (2013). Subthreshold bipolar disorder in a U. S. national representative sample: Prevalence, correlates and perspectives for psychiatric nosography. J Affect Disord 146:338-347.
23. Isaacson RL, Yoder PE, Varner J (1994). The effects of pregnenolone on acquisition and retention of a food search task. Behav Neural Biol 61:170-176.
24. Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D et al (2003). Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 6:127-137.
25. Kleinman LS, Lowin A, Flood E, Gandhi G, Edgell E, Revicki DA (2003). Costs of bipolar disorder. Pharmacoeconomics 21:601-622.
26. Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kilts JD, Bradford DW et al (2009). Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 34:1885-1903.
27. Marx CE, Trost WT, Shampine L, Behm FM, Giordano LA, Massing MW et al (2006a). Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology (Berl) 186:462-472.
28. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC et al (2006b). The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 60:1287-1294.
29. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld R M A, Petukhova M et al (2007). Lifetime and 12-month prevalence of bipolar spectrum disorder in the national comorbidity survey replication. Arch Gen Psychiatry 64:543-552.
30. Mitchell PB, Frankland A, Hadzi-Pavlovic D, Roberts G, Corry J, Wright A et al (2011). Comparison of depressive episodes in bipolar disorder and in major depressive disorder within bipolar disorder pedigrees. Br J Psychiatry 199:303-309.
31. Murakami K, Fellous A, Baulieu EE, Robel P (2000). Pregnenolone binds to microtubule-associated protein 2 and stimulates microtubule assembly. Proc Natl Acad Sci USA 97:3579-3584.
32. Nothdurfter C, Rupprecht R, Rammes G (2012). Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18 kDa) (TSPO). Curr Top Med Chem 12:360-370.
33. Osuji IJ, Vera-Bolanos E, Carmody TJ, Brown ES (2010). Pregnenolone for cognition and mood in dual diagnosis patients. Psychiatry Res 178:309-312.
34. Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW et al (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170:1249-1262.
35. Perlis RH, Brown E, Baker RW, Nierenberg AA (2006). Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry 163:225-231.
36. Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL et al (2012). Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry 73:924-930.
37. Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R et al (2010). Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry 71:1351-1362.
38. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359.
39. Rush AJ, Carmody T, Reimitz PE (2000). The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 9:45-59.
40. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L et al (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 356:1711-1722.
41. Schaffer A, Cairney J, Veldhuizen S, Kurdyak P, Cheung A, Levitt A (2010). A population-based analysis of distinguishers of bipolar disorder from major depressive disorder. J Affect Disord 125:103-110.
42. Serra M, Pisu MG, Littera M, Papi G, Sanna E, Tuveri F et al (2000). Social isolation-induced decreases in both the abundance of neuroactive steroids and GABA (A) receptor function in rat brain. J Neurochem 75:732-740.
43. Sripada RK, Marx CE, King AP, Rampton JC, Ho SS, Liberzon I (2013). Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biol Psychiatry 73:1045-1053.
44. Sripada RK, Welsh RC, Marx CE, Liberzon I (2014). The neurosteroids allopregnanolone and dehydroepiandrosterone modulate resting-state amygdala connectivity. Hum Brain Mapp 35:3249-3261.
45. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J et al (1996). A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 53:777-784.
46. Torrey EF, Davis JM (2012). Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses 5:208-216.
47. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E et al (1998). Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95:3239-3244.
48. Vallee M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martin-Garcia E et al (2014). Pregnenolone can protect the brain from cannabis intoxication. Science 343:94-98.
49. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435.
50. Zorumski CF, Mennerick S (2013a). Neurosteroids as therapeutic leads in psychiatry. JAMA Psychiatry 70:659-660.
51. Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S (2013b). Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 37:109-122.